NanoVision Diagnostics is commercializing a breakthrough cancer technology that can sooner detect and more accurately predict the risk of progression through the optical analysis of a standard biopsy slide. Their patented microscope has 1000x better sensitivity than an optical microscope, enabling it to detect molecular scale changes that are not visible through conventional pathology. Molecular changes manifest prior to cellular changes, allowing earlier and more accurate detection. The company is initially focused on the detection and prognosis of breast cancer, with plans to expand to the study of multiple cancer strains in the future.
NanoVision Diagnostics has received investment from the North Coast Angel Fund.